|drug2456||MySafeRx Inspire Flex Wiki||1.00|
|drug2457||MySafeRx Inspire Plus Wiki||1.00|
|drug2981||Placebo oral tablet Wiki||0.18|
There is one clinical trial.
This is a double-blind, randomized, placebo-controlled clinical trial. A total of 210 individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who came to the study site with clinical and radiological suspicion of SARS-CoV2, will be randomized into two treatment groups at a 1:1 ratio to receive a 5-day CQ diphosphate tablets or placebo (tablet without active ingredient produced with the same physical characteristics).
Description: Evaluate if CQ diphosphate prevents the onset of SARS in patients on intervention group through standardized questionnaires.Measure: Proportion of patients with onset of severe acute respiratory syndrome (SARS) Time: 7 days after randomization
Description: Mortality rate between intervention and placebo group on days 7, 14, and 28 after randomizationMeasure: Mortality rate Time: after randomization, up to 28 days
Description: Proportion of participants in need and duration of intensive care support after randomizationMeasure: Number of participants in need of intensive care support Time: during and after intervention, up to 28 days
Description: Viral load change in blood and oropharyngeal swab samplesMeasure: Viral concentration Time: After randomization, up to 7 days
Description: Incidence of serious adverse events during and after treatmentMeasure: Cumulative incidence of serious adverse events Time: During and after intervention, up to 28 days
Description: Incidence of grade 3 and 4 adverse events during and after treatmentMeasure: Cumulative incidence of grade 3 and 4 adverse events Time: During and after intervention, up to 28 days
Description: proportion of discontinuation or temporary suspension of treatment (for any reason)Measure: Proportion of patients with discontinued treatment Time: after randomization, up to 28 days
Description: proportion of patients with increased levels of troponin IMeasure: Incidence of cardiac lesions Time: after randomization, up to 120 days
Description: proportion and magnitude of QTcF interval increases higher than 500msMeasure: Incidence of cardiac disfunctions Time: after randomization, up to 120 days
Description: Changes measured on day 120 will be compared to baseline, through spirometry.Measure: Change in respiratory capacity Time: Day 120 after randomization
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports